Investor briefing-AD-214 top line single dose safety results
Filed with ASX · · 35 pages · English
In the deck
Earlier from AdAlta
- Appendix 4D and Interim Financial Report
- FDA Orphan Drug Designation for AD-214
- Phase I HV extension to explore encouraging results
- AGM Presentation
- AusBiotech presentation including Phase I status update
Later from AdAlta
- Mutiple Dose Part Of Ad-214 Phase I Trial Commenced
- AdAlta granted Japanese patent for AD-214
- GE Healthcare collaboration advances to next stage
- R&D Tax Incentive Facility
- AdAlta secures AD-214 resupply
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta